Monday, September 20, 2010

ACTC Stock Patent Ignites Interest

On September 14 Advanced Cell Technology released new concerning their Stem Cell-Derived RPE Cells to Treat Eye Disorders. The company reports their patent covers 41 claims covering Stargardt’s disease, retinitis pigmentosa, and macular degeneration.

“We believe that these patents are especially important as they extend the company’s patent coverage of the scalable manufacturing of human RPE cells for therapeutic use, which are core to our technology and product portfolio,” continued Mr. Caldwell. “This IP further expands our patent estate with respect to protecting the use of RPE cells in a wide range of treatments, offering additional validation of the strength and breadth of our patent portfolio. This development also dovetails nicely with the prospect of initiating our human clinical trial for our RPE program. We are optimistic that the methods-of-treatments and the culturing processes covered by these two new patents, along with the Company’s proprietary detection technique for final product release, will establish a formidable barrier to entry for any potential competitors. Once we have begun to treat Stargardt patients, we plan to initiate another clinical trial relating to the use of RPE cells in the treatment of dry Age-Related Macular Degeneration (AMD). At present there is no approved treatment for dry AMD, despite the fact that it represents a $20-30 billion potential market.”

Penny Markets contributers are not registered investment advisors. Prior to any investment please consult an investment advisor. Investment in pennystocks can, and often does result in total loss of investment.

Have you considered the alternative to traditional investor relations? Alternative investor relations has evolved to assist corporations drive sales and increase earnings. Visit the investor relations page to find out more! 

Connect with other ACTC investors on the ACTC investors social network

No comments: